Massive study reveals COVID's hidden cost: how many workdays did paxlovid save?
NCT ID NCT07072793
Summary
This study aimed to understand the economic impact of COVID-19 on the workforce by measuring missed workdays and associated costs. It analyzed over 131,000 US workers with mild-to-moderate COVID-19 who were at high risk for severe disease, comparing those who took the antiviral Paxlovid to those who were eligible but did not. The goal was to see if the medication helped people return to work faster and reduced the financial burden of sick leave.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 (CORONAVIRUS DISEASE 2019) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.